Anorexia and Medical Marijuana: What Research Shows
Anorexia and Medical Marijuana: What the Research Shows
Anorexia is one word for two different situations. Anorexia nervosa is a psychiatric eating disorder in which a person restricts food despite being underweight. Medical anorexia is appetite that has quietly disappeared, usually next to cancer, kidney failure, HIV, surgery, or simply advanced age. The published research on cannabis treats these two as separate problems, with separate answers, and so does this page.
Based on 219 peer-reviewed studies published between 1976 and 2026 · Research current as of September 4, 2026
Does anorexia qualify you for a medical marijuana card?
The honest answer is that your state decides, not us and not your doctor. Every medical marijuana program keeps its own list of qualifying conditions, and the wording on that list is what a physician has to match you against.
Some programs name anorexia directly. Many more do not use that word at all and instead cover the same patient under cachexia — the medical term for severe weight and muscle loss driven by another illness — or under a phrase like “severe wasting syndrome.” If you have lost a significant amount of weight because of cancer, HIV, kidney failure, or the treatment for one of them, you may qualify under that heading even though your paperwork never says anorexia.
A third group of states has neither word on the list but allows a licensed physician to certify a debilitating condition based on your symptoms, or keeps a petition process for adding conditions. That is a conversation for the appointment, and it is one of the reasons the evaluation exists.
Anorexia is named in your state
The cleanest case. You bring records that show the weight loss and how long it has lasted, and the physician evaluates you against that listed condition.
It is listed as cachexia or wasting
Very common. The qualifying line is the wasting caused by your primary illness, so the underlying diagnosis and the documented weight loss are what matter.
Neither one is on the list
Then a card for appetite loss alone may not be available where you live. Ask whether another condition you already carry is on the list, and whether your state accepts petitions.
What the program in your state actually involves
Qualifying is the first of two doors. In most states a physician’s recommendation is followed by registration with the health department, which issues the card itself and enters you in a confidential patient registry; in a few states the recommendation alone is what a dispensary asks for. Either way, buying happens at licensed dispensaries, where products are lab-tested and labeled with their THC and CBD content — which matters more than usual here, because the doses in the studies on this page are measured in single milligrams.
What the card grants beyond access differs by state and is worth reading before you apply: the amount you may hold, whether you may grow, whether medical-only products and higher-strength formulations are available to you, and how much tax you pay compared with a recreational buyer. Those rules, and the qualifying list itself, are set out state by state on the laws and regulations pages.
Anorexia nervosa or loss of appetite: one word, two conditions
Before anything else is worth reading, it helps to know which of these two describes you. They look similar on a chart — a falling weight, a plate left unfinished — and they are treated in almost opposite ways.
Anorexia nervosa
A psychiatric eating disorder. Appetite may still be present; what drives the illness is fear of weight gain and a distorted sense of body size, so food is restricted on purpose. It most often begins in adolescence or early adulthood and affects women far more often than men, though men are diagnosed too and are often diagnosed late.
Care today is built on psychotherapy (family-based treatment for adolescents, CBT-E for adults), supervised nutritional rehabilitation, and medical monitoring of the heart, bones, and electrolytes. No medication is approved to treat the disorder itself. Cannabinoid research here is early and small: the largest thing published is a randomized pilot of cannabidiol in 32 people that ran for 21 days and was never designed to prove benefit [1].
Anorexia as loss of appetite, and cachexia
Here the desire to eat is genuinely gone, and usually another illness is driving it: advanced cancer, HIV, kidney failure, systemic sclerosis, recovery from major abdominal surgery, or the ordinary appetite decline of older age. When weight and muscle fall away despite adequate intake, clinicians call it cachexia, and it is a marker of how the primary disease is going.
Care starts with the underlying illness, then nutritional support, exercise where it is possible, and appetite-stimulating medication — in the United States most often megestrol acetate or dronabinol, the prescription form of THC. This is the group in which cannabinoids have actually been tested, in cancer, in older adults, in kidney failure [2][3].
This is why two people can read the same study and take away opposite things. In cachexia the goal is to make eating possible again, and an appetite signal is exactly what is missing. In anorexia nervosa the appetite signal is not the broken part, so a drug that increases hunger does not touch the illness — and in a person who fears weight gain, it can raise anxiety rather than lower it. Researchers have also found a shared genetic tendency between anorexia nervosa and starting cannabis use at all (genetic correlation 0.23, p = 0.0001), which is a reason for caution rather than for enthusiasm [4].
The other strand of work on the left-hand column is biological rather than therapeutic. A case-control study set 38 women with anorexia nervosa against 40 controls and found the CNR1 and FAAH genes — the blueprints for the cannabinoid receptor and for the enzyme that clears the body’s own cannabinoids — carrying different chemical tags in the two groups (p < 0.0001) [5]. That is good evidence that the endocannabinoid system is involved in the illness. It is not evidence that adding cannabis to it helps, and the distinction matters more here than almost anywhere else on this page.
What is standard care today, in both columns
For anorexia nervosa, the treatments with the best evidence are talking treatments plus supervised refeeding. In adolescents that usually means family-based treatment, where parents take charge of meals for a period; in adults, a form of cognitive behavioral therapy built for eating disorders. Weight restoration is monitored medically because the heart rhythm, the electrolytes, and the bones are all at stake, and the early phase of refeeding carries its own risks. No drug is approved to treat the disorder, and medication is used for the conditions that travel with it — depression, anxiety — rather than for the eating disorder itself.
For appetite loss and cachexia, care starts one level up: treat the illness driving it, then support intake. That means dietitian input, energy-dense food and supplement drinks, managing the things that make eating unpleasant — nausea, mouth pain, constipation, depression — and physical activity where the person can manage it. When that is not enough, physicians in the United States reach for an appetite stimulant, most often megestrol acetate, sometimes dronabinol. Both of those are prescriptions, and both were compared with cannabinoids in the studies further down this page [2].
Neither column has cannabis as a first-line treatment anywhere. That is the honest frame for everything that follows: this is a question about an addition to care, asked by people for whom the standard route has not been enough.
Not sure which one describes you? The questions below sort that out.
Is my kind of appetite loss the kind cannabis is studied for?
Twelve questions about your weight, your health, and your medications. At the end you get a plain reading of what your answers point to, what the research says about that situation, and what to raise with a physician. Nothing is stored against your name, and this is not a diagnosis.
12 questions · about a minute · your answers stay in this browser
How the endocannabinoid system controls hunger
Your body makes its own cannabis-like molecules. They are called endocannabinoids, and together with the receptors they dock into — CB1 and CB2 — and the enzymes that clear them away, they form the endocannabinoid system. It behaves less like a switch and more like a thermostat, nudging appetite, nausea, pain, mood, and sleep back toward the middle.
The appetite part of that thermostat runs largely through CB1 receptors in the hypothalamus, the small region at the base of the brain that keeps track of energy. When CB1 is activated there, the brain releases more neuropeptide Y, one of the strongest hunger signals it has, and the signaling cascade that carries ghrelin’s message is turned up as well [7]. THC is an appetite stimulant for the plain reason that it lands on the same CB1 receptor the body uses for this job.
Ghrelin is the hormone the empty stomach sends out to say that it is time to eat — a short chain of 28 amino acids, reading a receptor called GHS-R1a that is 366 amino acids long and that idles at roughly half of its maximum activity even with no ghrelin present [7]. The interesting part for this page is that GHS-R1a and the CB1 receptor pair up physically. In that paired state the calcium signal that ghrelin triggers is about 140% of what the ghrelin receptor produces alone [7]. The hunger hormone and the cannabinoid system are not two separate stories.
Two more findings are worth knowing, and both come with a caveat attached. In animal work — an experiment in 176 broiler chicks, not in people — blocking CB1 or CB2 made the appetite-suppressing peptide LEAP-2 suppress feeding even more strongly, while blocking the ghrelin receptor blunted it [8]. That is a clean demonstration of the wiring, in birds. And in women with anorexia nervosa, the CNR1 gene that codes for CB1 and the FAAH gene that codes for the enzyme clearing endocannabinoids both showed altered methylation — chemical marks that change how strongly a gene is read — compared with controls (p < 0.0001) [5]. That points to the endocannabinoid system being involved in the disorder. It does not point to cannabis being its treatment.
Appetite also runs on hormones that push the other way, and cannabinoids do not obviously move them. In a crossover trial in older adults with poor appetite, an oromucosal THC and CBD spray did not significantly change GLP-1, the hormone that signals fullness (Bonferroni-corrected p = 0.274 across 17 participants) [9]. The system has more than one lever, and THC pulls only some of them.
What the research actually found
Studies are not equal. A randomized trial that compares a cannabinoid against a placebo can tell you whether the drug did the work; a case report tells you what happened to one person. What follows is organized from the strongest designs down, and split by the group of patients studied, because the answer is different for each.
Cancer-related anorexia and cachexia
This is where the strongest trial on the subject sits, and it is a negative one. In a multicenter phase III trial, 289 patients with cancer-related anorexia-cachexia were screened, 243 were randomized to cannabis extract, THC alone, or placebo, and 164 completed the 42-day course. Neither cannabis arm beat placebo on appetite or quality of life, and the trial was stopped early because the arms were not separating [10].
Later syntheses have not overturned that. A 2022 systematic review and meta-analysis of cannabinoid interventions for cachexia outcomes in cancer rated the certainty of the evidence very low and called the picture inconclusive [11]. A 2024 systematic review focused on older adults with cancer-related anorexia pooled 6 studies and 869 participants and found the results inconsistent from study to study; in the comparisons available, megestrol acetate improved appetite in about 75% of patients against 49% on dronabinol [2]. In other words, in this group a cannabinoid is a reasonable option to discuss, not the first one on the shelf.
Anorexia of aging and other medical causes
The newer work here is small and largely neutral. In a double-blind crossover trial, 17 older adults with poor appetite received an oromucosal THC and CBD spray or placebo; neither GLP-1, nor total ghrelin, nor how hungry people said they felt moved significantly [9]. A pharmacokinetic study in 20 similar patients explains part of why: absorption of THC through the lining of the mouth varied enormously between individuals, so the same three sprays did not produce the same drug level in the blood [12].
Outside oncology and aging, two small trials point in a mildly positive direction. In systemic sclerosis, 27 patients were randomized to cannabis oil or placebo for 4 weeks, titrated to an average of 2.92 mg THC and 3.24 mg CBD a day, with mixed results on appetite and quality of life [13]. In an open-label phase 1b trial without a control group, 12 people with kidney failure took cannabidiol for 6 weeks, 7 completed it, 2 stopped because of side effects, and average scores improved in 8 of the 12 symptom domains measured [3]. Neither study is large enough to settle anything, and the second had nothing to compare itself against.
Anorexia nervosa
Here the evidence is thinnest, and it is the group most likely to be reading this page. The largest signal comes from a scoping review of cannabis and anorexia nervosa, which found that dronabinol produced a small weight gain against placebo — a mean difference of 1.0 kg (95% CI 0.40–1.62, p = 0.03) — in a short trial in adult women, with tiredness, dizziness, disorientation, anxiety, and hallucinations reported alongside it [14]. A 2026 randomized placebo-controlled pilot of cannabidiol in 32 participants over 21 days was designed to test safety rather than cure anything; body mass index moved differently in the two groups over time (p = 0.046, partial eta squared 0.252), and the authors themselves list the short duration, the absence of male participants, and expectancy effects as limits [1].
The rest of the literature in this group is about association, not treatment. Anorexia nervosa and starting cannabis use share genetic risk (correlation 0.23, p = 0.0001), as do anorexia nervosa and alcohol use disorder (0.18, p = 0.0006) [4]. In a nationwide cohort, people with an eating disorder and a co-occurring substance use disorder carried the physical-illness risks of both, added together [15]. None of that says cannabis treats the eating disorder. It says the two travel together often enough that a physician will ask.
Browse the studies yourself
Every study named on this page is below, with its design, who was in it, and what came out — including the neutral and negative results. Filter by the kind of evidence you want to see.
Cannabis extract and THC in cancer-related anorexia-cachexia
Of 289 patients screened, 243 were randomized and 164 finished 42 days of treatment. Neither the whole-plant extract nor THC alone improved appetite or quality of life more than placebo, and the trial ended early [10].
Cannabidiol in anorexia nervosa
A 21-day pilot testing safety, drug levels, and symptom change in women with anorexia nervosa. Body mass index followed a different path in the two groups over the study period (p = 0.046, partial eta squared 0.252). Small, short, and not designed to prove benefit [1].
Cannabis oil for appetite in systemic sclerosis
Fourteen patients took cannabis oil and 13 took placebo for 4 weeks, titrated to an average of 2.92 mg THC and 3.24 mg CBD per day, reaching 45.2 kcal/kg of daily intake at follow-up in the treatment group. Results were mixed across appetite and quality-of-life measures; somnolence and dizziness each appeared in 2 patients [13].
An oromucosal THC and CBD spray against placebo in poor appetite
Each participant received both the spray (8.1 mg THC and 7.5 mg CBD) and placebo. GLP-1, total ghrelin, and self-reported appetite did not change significantly (corrected p = 0.274 for the GLP-1 comparison) [9].
Cannabinoids for cancer-related anorexia in older adults
Findings differed from study to study, so the review reached no firm conclusion. Where the two were compared, megestrol acetate improved appetite in about 75% of patients versus 49% on dronabinol. Doses in the included studies typically started around 2.5 mg of THC [2].
Cannabinoid interventions for cachexia outcomes in cancer
Pooled the available trials and graded the certainty of the evidence as very low, mainly because the studies were small, differed in method, and lost many participants along the way. The conclusion was inconclusive rather than negative [11].
The relationship between cannabis and anorexia nervosa
Mapped everything published on the pairing. The treatment signal was a weight gain of 1.0 kg against placebo on dronabinol (95% CI 0.40–1.62, p = 0.03), with tiredness, dizziness, disorientation, anxiety, and hallucinations among the reported effects. It also covers a genetic association with a CNR1 variant (odds ratio 0.799, 95% CI 0.653–0.976) [14].
Appetite loss after major abdominal surgery
Not a cannabis study, and included here because it sets the baseline: appetite loss after surgery is common and often resolves on its own. Simple measures mattered — chewing gum shortened the time to the first feeling of hunger by 21.2 hours (95% CI 13.65–28.77), with bloating and indigestion as trade-offs [6].
Shared genetic risk between eating disorders and substance use
Anorexia nervosa shares measurable genetic risk with cannabis initiation (correlation 0.23, p = 0.0001) and with alcohol use disorder (0.18, p = 0.0006). A statement about populations and inherited tendency, not about whether cannabis helps or harms an individual patient [4].
CNR1 and FAAH methylation in anorexia nervosa
Women with anorexia nervosa carried different chemical marks on the gene for the CB1 receptor and on the gene for the enzyme that breaks down the body’s own cannabinoids than controls did (p < 0.0001). Evidence that the endocannabinoid system is involved in the disorder [5].
Cannabidiol for symptom burden in kidney failure
Six weeks of CBD with a follow-up at week 10. Seven participants completed therapy, 2 stopped because of side effects, and across 70 responses the average score improved in 8 of 12 symptom domains. With no placebo group, improvement cannot be separated from expectation [3].
How much THC actually reaches the blood from a mouth spray
In older patients with poor appetite, three sprays of a product delivering 2.7 mg THC and 2.5 mg CBD each produced an average peak THC level of 4.25 µg/L — but the variation between individuals was large, and absorption took about 1.35 hours on average [12].
Physical illness risk when an eating disorder meets substance use
Patients carrying both diagnoses had the risks of each added together rather than multiplied. Relevant to anyone considering daily cannabis use alongside an active eating disorder [15].
Alcohol and cannabis use patterns in binge-spectrum eating disorders
Adults sorted into distinct use patterns, and those patterns tracked with personality features rather than with eating-disorder severity. Descriptive, and no help in deciding on treatment [16].
Substance fixation in autism leading to anorexia nervosa
A young patient whose daily cannabis use came with appetite suppression, sleep deprivation, and withdrawal symptoms, and in whom anorexia nervosa developed. One person’s story, and a counterweight to the assumption that cannabis always raises appetite [17].
Weight loss that turned out to be intestinal tuberculosis
A 39-year-old with chronic abdominal pain and weight loss was found to have a 5 mm intestinal perforation requiring surgery. Included as a reminder that unexplained weight loss deserves a diagnosis before it gets a treatment [18].
How the cannabinoid and ghrelin systems interact in feeding
In animals, not in people: blocking either the CB1 or the CB2 receptor made the appetite-suppressing peptide LEAP-2 cut food intake even further, while blocking the ghrelin receptor blunted that effect. Mechanism, not treatment [8].
No studies of that design are on this page.
Cannabis for nausea and vomiting — the symptom that most often travels with appetite loss, covered on its own page.
How big is the effect, in numbers
“It helps” is not a useful sentence. What follows is the size of the effect where researchers measured one, with the interval that shows how precise the measurement was.
Read that interval rather than the headline. The true effect sits somewhere between 0.4 and 1.6 kg, which is real but modest — roughly the weight of a large bottle of water, over the length of a short trial. It is also the single clearest number anyone has produced for this question.
In the 2026 pilot of cannabidiol in anorexia nervosa, body mass index followed a different trajectory in the treated group over 21 days (p = 0.046, partial eta squared 0.252) [1]. That statistic describes how much of the variation between the groups was associated with the treatment in a 32-person pilot — a hint worth following up, not a result to act on.
Against another appetite drug, cannabinoids came second. In the studies pooled by a 2024 systematic review, megestrol acetate improved appetite in about 75% of patients versus 49% on dronabinol [2]. And the largest randomized trial in this field, 243 patients over 42 days, found no superiority for either a cannabis extract or THC over placebo at all [10]. A trial that large finding nothing is itself a number, and an important one.
Where an effect was expected and not found, that is stated too: in older adults with poor appetite, an oromucosal spray did not significantly shift GLP-1, total ghrelin, or how hungry people reported feeling [9].
Where the evidence runs out
About a third of the published studies on cannabinoids and appetite end without a clear answer — mixed, neutral, or inconclusive. That is not a reason to dismiss the field, and it is a reason not to call anything here settled. These are the specific holes.
- The trials are tiny. Seventeen people. Twelve. Thirty-two. Twenty-seven. At those sizes a real effect can hide and a fluke can look convincing, and the authors of these papers say so themselves [9][3][1].
- They are short. Three weeks, four weeks, six weeks. Appetite loss in a chronic illness lasts months or years, and nobody has followed patients on cannabinoids for that long [1][13].
- People drop out. In the largest trial, 243 patients were randomized and 164 finished [10]. In the phase 1b kidney-failure trial, 7 of 12 completed six weeks [3]. When the sickest participants leave, what remains looks better than the truth.
- Outside cancer, there is almost nothing. Reviewers name the lack of data beyond oncology explicitly [11]. For anorexia of aging, kidney failure, and systemic sclerosis, the total human evidence is a handful of small studies.
- The results disagree with each other. A systematic review of six studies in older adults could not pool them into a conclusion because the findings pointed different ways [2].
- Dose and absorption are unpredictable. The same spray produced very different blood levels in different patients, which means “the dose used in the study” is not the dose that reached the patient [12].
- For anorexia nervosa, nobody has tested whether it helps the illness. The existing trial tested safety and drug levels. Whether cannabinoids change the course of an eating disorder is an open question, and the honest answer today is that we do not know [1].
Doses used in studies — and why that is not a prescription
Everything in this section describes what researchers gave participants under supervision. None of it is a recommendation, a starting point, or a plan. Your dose, if you end up with one, comes from a licensed physician who knows your weight, your diagnosis, and every other medicine you take.
The pattern across the literature is the same one clinicians use with any sedating drug: start very low, go up slowly, stop when the benefit and the side effects balance. In the studies of older adults with cancer-related anorexia, THC typically started around 2.5 mg [2]. In the systemic sclerosis trial, four weeks of titration landed at an average of 2.92 mg THC and 3.24 mg CBD a day — small amounts, reached gradually [13]. A crossover trial in older adults used a single larger exposure of 8.1 mg THC and 7.5 mg CBD, delivered as a mouth spray containing 2.7 mg THC and 2.5 mg CBD per spray [9][12].
Dronabinol deserves a separate note, because it is the form that appears most often in this research. It is synthetic THC in a capsule, available by prescription in the United States, dosed in milligrams like any other medicine. It is not the same thing as buying a product at a dispensary, and a medical card does not get you a dronabinol prescription — that comes from your treating physician.
| Route | Onset | Duration | What to keep in mind |
|---|---|---|---|
| Inhaled (vaporized) | Fastest | Shortest | Easiest to titrate by feel, hardest on the airways. Rarely used in the studies above, which favored oral and oromucosal products. |
| Oral (capsule, oil, edible) | Slowest | Longest | The form used in most of this research. Taking CBD with food increases how much is absorbed, so a dose on an empty stomach and the same dose after a meal are not equivalent [1]. |
| Oromucosal spray or tincture | Between the two | Between the two | Absorption through the lining of the mouth varies a great deal from person to person, which makes the delivered dose less predictable than the label suggests [12]. |
One practical note that has nothing to do with cannabis: in appetite loss after abdominal surgery, plain measures were what the evidence supported, including chewing gum, which brought the first feeling of hunger forward by 21.2 hours on average (95% CI 13.65–28.77) [6]. Small, unglamorous, and better studied than most of what is on this page.
Working it out alone against working it out with a physician
Plenty of people have already tried cannabis for this before reading anything about it, and they usually describe the same three problems. The product changes between purchases, so a dose that worked once does not repeat. Nothing is being measured, so “it helps” and “I feel better about eating” blur together and no one can tell whether weight actually moved. And nobody has checked the combination against the rest of the medicine cabinet, which is where the avoidable harm in this literature comes from.
A supervised route does not make cannabis work better. It makes the attempt legible: a starting point chosen with your diagnosis in view, a labeled product with known THC and CBD content, a defined period to test it, a weight and a symptom recorded before and after, and a physician who knows what your other prescriptions do. It also produces a decision at the end — keep going, change the product, or stop, which is the decision most self-directed attempts never reach. And it is legal, documented, and yours to show if anyone asks.
Side effects and drug interactions
This is the part of the page a physician will spend the most time on with you, and the part where the evidence is clearest — because side effects get recorded even in trials that fail to show a benefit.
The effects reported most often in this literature are tiredness, dizziness, disorientation, anxiety, and, less commonly, hallucinations [14]. In the cannabidiol pilot in anorexia nervosa, abdominal symptoms appeared in 6% of the CBD group and a nonspecific rash in 6% of participants overall [1]. In the systemic sclerosis trial, somnolence and dizziness were each reported by 2 patients out of 14 in the treatment arm [13]. In the kidney-failure trial, 2 of 12 participants stopped therapy because of side effects [3]. In a person who is already underweight, dizziness is not a minor complaint: a fall carries further when there is nothing left to cushion it.
Two risks belong specifically to this diagnosis. The first is cannabinoid hyperemesis syndrome — cycles of severe vomiting in people who use cannabis daily over long periods, described in case reports and the exact opposite of what someone with appetite loss needs [14]. The second is dependence. Anorexia nervosa and substance use travel together in the data, and when both are present the physical risks add up rather than cancel out [15][4]. A case report describes a young patient in whom heavy daily use came with appetite suppression, disturbed sleep, and withdrawal [17].
Interactions worth raising at the appointment
Open each one. These are what the studies on this page recorded, not a complete list — the complete list is the one your physician builds from your own prescriptions.
Megestrol acetate, the other appetite drug
Not a dangerous combination, but a comparison you should have. In the studies pooled by a 2024 systematic review, megestrol acetate improved appetite in about 75% of patients against 49% on dronabinol [2]. If your oncologist has already offered megestrol, that number is the reason.
Food, and why timing changes the dose
Taking CBD with food increases how much of it is absorbed [1]. For someone eating irregularly — which is the whole point of this page — that means the effect of the same capsule can swing from day to day depending on whether a meal happened.
Medicines handled by the same liver enzymes
Trials of cannabinoids routinely exclude people taking medicines such as warfarin, carbamazepine, rifampicin, fluoxetine, clobazam, and fluoroquinolone antibiotics, because cannabinoids and those drugs compete for the same processing pathways in the liver. Exclusion from a study is not proof of harm, but it is the reason your full medication list has to be on the table before anything is decided.
Reduced kidney or liver function
Clearance of cannabinoids in people with kidney failure is not well mapped, and the trial in that population recommends monitoring liver function during treatment [3]. Older patients fall into the same caution for the same reason: the drug lingers unpredictably.
An eating disorder plus regular substance use
In a nationwide cohort, carrying both an eating disorder and a substance use disorder meant carrying the physical risks of both, added together [15]. If you have an active eating disorder, this is the single strongest argument for involving your treating clinician before adding anything.
Driving, machinery, and the first few doses
Tiredness, dizziness, and disorientation are the most frequently recorded effects in this literature [14]. Until you know how a product affects you, driving and operating machinery are off the table, and someone should know you have taken it.
Who should not use cannabis for this
Some of these are absolute, some mean “only with the specialist who treats you.” Either way, they are the lines the studies themselves drew.
- Pregnancy and breastfeeding. Cannabinoid trials exclude pregnant and nursing participants as a matter of protocol, so there is no evidence of safety here — and appetite loss in pregnancy has its own causes that need their own assessment.
- Active psychosis, schizophrenia, or a history of it. The same exclusion appears in trial after trial, and hallucinations and disorientation are among the effects recorded in this literature [14].
- An active eating disorder without a treating clinician. This is the situation the page is most careful about. The evidence that cannabinoids help anorexia nervosa is a single small pilot [1], while the evidence that eating disorders and substance use compound each other’s physical risks comes from a nationwide cohort [15]. Get the treatment team in place first.
- Medicines that share a processing pathway. Warfarin, carbamazepine, rifampicin, fluoxetine, clobazam, and fluoroquinolone antibiotics are the ones study protocols name. Bring the whole list, including over-the-counter products.
- Kidney failure and advanced age. Clearance is unpredictable, liver function needs watching, and the one trial in kidney failure had 2 of 12 participants stop because of side effects [3].
- Active cancer treatment, especially immunotherapy. Not a prohibition, a hand-off: this decision belongs to your oncologist, who knows what your regimen tolerates. The strongest trial in cancer-related cachexia found no benefit over placebo [10], so there is little to trade away by asking first.
- Daily heavy use already causing vomiting. Repeated cycles of severe vomiting in long-term daily users are described in the case literature [14]. More cannabis makes that worse, not better.
Talk to a licensed physician about whether any of these apply to you.
What this means if you are considering it
Most people arrive at this conversation braced for a lecture. You are far more likely to get a set of practical questions — and the appointment goes better when you have the answers ready.
What to write down before the appointment
- Your weight, with dates. Two or three points over the last months are worth more than an estimate. Use the same scale, at the same time of day.
- What you actually eat in a day. Two ordinary days, written down without editing. “Coffee, half a sandwich at four, nothing after” tells a physician more than “not much.”
- Every medicine and supplement, with doses. This is the part that changes the answer most often, for the reasons in the section above.
- Your diagnoses, including the psychiatric ones, and the name of whoever treats them.
- What you have already tried — appetite stimulants, supplement drinks, smaller frequent meals, cannabis in any form — and what happened.
- What you want out of this. Eating one proper meal a day, holding your weight steady, sleeping through the night: name the goal, because that is what gets measured later.
Questions worth asking
- Does my condition qualify under my state’s list, and under which wording?
- Given my other medicines, is a cannabinoid a reasonable thing to try at all?
- Would a prescription appetite medicine be the better first step for me?
- How will we tell in a month whether this is working, and what do we do if it is not?
- What side effect means stop and call, rather than wait it out?
An evaluation makes sense if
Your appetite has been gone for weeks or months and a diagnosed illness explains it. You are losing weight despite trying. You have already discussed it with the physician treating that illness, or you are ready to. You want a legal, documented route with a licensed physician rather than guesswork, and you understand from this page that the expected benefit is modest.
It is not the right step if
You are in the acute phase of an eating disorder and not in treatment. You are pregnant or nursing. You are hoping cannabis will replace nutrition, chemotherapy, dialysis, or psychotherapy. You have never had the weight loss looked at by a physician — that comes first, because unexplained weight loss sometimes has a cause that surgery, not a card, resolves [18].
How to get a medical marijuana card for appetite loss
The process is the same whether your qualifying line reads anorexia, cachexia, or the illness underneath it. Four steps, all of them from home.
1. Fill out the intake form
About five minutes. Your symptoms, your diagnoses, your medications.
Have your weight history and your medication list nearby.
2. Meet the physician by video
About fifteen minutes of consultation. You agree the time with the physician.
Keep an hour free rather than a minute — appointments can run late.
3. Receive the signed recommendation
Usually within 24 to 48 hours after the appointment, if the physician approves you.
It arrives in your account, ready to use or to file with the state.
4. Register with your state program
Some states require this step, some do not. The timeline belongs to the agency.
Each state sets its own processing time, and we do not promise one on their behalf.
What you end up with
A signed recommendation from a licensed physician, valid in the state you were evaluated in, in a form your state’s program accepts — a digital copy you can show at a dispensary, and the document the health department needs if registration is required where you live. It names the qualifying condition, which is the part that matters when the wording is cachexia rather than anorexia. You also get the appointment itself: fifteen minutes with a physician who reads your medication list and says out loud whether this is a sensible thing for you to try, which is the part that self-directed use never includes.
Across 228 reviews written by patients from every state we work in. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated — everyone who has been through an appointment with us, in every state where we are licensed
- Since 2018doing only this: online evaluations for medical cannabis programs, and nothing else on the side
Everything you receive lives in one place afterward: your account and documents, where the recommendation can be downloaded again if a dispensary or an employer’s process asks for it. If you want the mechanics in full — what the card is, what it is not, and how states differ — that is on how the card works, and the questions that come up most often are answered on our common questions page.
Two groups have their own route: veterans and low-income patients.
Questions patients ask
Does anorexia qualify for a medical marijuana card in my state?
It depends entirely on how your state wrote its list. Some name anorexia, more of them cover the same patient as cachexia or severe wasting, and some allow a physician to certify a debilitating condition without naming it. Check the wording where you live on medical marijuana laws by state, then bring your records to the evaluation.
Is cannabis dangerous if I have an eating disorder?
It carries real risk, and the honest answer is that it should not be a solo decision. Eating disorders and substance use disorders occur together often, and when they do, the physical risks add up [15]. There is also shared genetic risk between anorexia nervosa and starting cannabis use [4]. If you have an active eating disorder, the first step is a treating clinician, not a card.
Does it help with cancer-related cachexia?
Less than most people expect. The largest randomized trial, 243 patients over 42 days, found no advantage over placebo for either a cannabis extract or THC [10], and a meta-analysis of cachexia outcomes rated the evidence very low certainty [11]. Where cannabinoids were compared with megestrol acetate, megestrol did better on appetite, 75% against 49% [2]. It is a conversation to have with your oncologist, not a reason to change your treatment.
What is dronabinol, and how is it different from the plant?
Dronabinol is synthetic THC in a capsule, prescribed and dosed in milligrams, and it is the form used in most of the research on this page. A dispensary product contains THC alongside CBD, other cannabinoids, and terpenes in proportions that vary between batches. A medical card gives you access to dispensary products; a dronabinol prescription comes from your treating physician.
Will my card work in another state?
Sometimes. A number of states recognize out-of-state patient cards for purchase, others recognize nothing at all, and the conditions accepted may differ from the ones your home state accepts. Check the destination state on the state laws pages before you travel, and never assume your card travels with you.
My condition is not on my state’s list. What now?
Two things are worth checking. First, whether the illness causing your weight loss is itself on the list — cancer, HIV, and several chronic conditions usually are, and that is the qualifying line for many patients with appetite loss. Second, whether your state has a petition process for adding conditions, or a general debilitating-condition clause a physician can certify under. If neither applies, a card for this alone may not be available where you live.
Does a card replace my treatment?
No, and nothing in the research suggests it could. Cannabinoids are studied as an addition to nutritional support, treatment of the underlying illness, and psychotherapy where an eating disorder is involved. Stopping any of those to try cannabis is the one move this page argues against throughout.
What does an evaluation cost, and what if I am not approved?
The price of the evaluation is shown before you pay, on the medical card page, and it covers the consultation with the licensed physician and the signed recommendation if you are approved. State registration fees, where a state charges them, are paid to the agency and are separate. If the physician concludes you do not qualify, you will be told why during the appointment, and what would need to change for that answer to be different.
How does renewal work?
Recommendations expire, and most states run on an annual cycle. Renewal is the same process in miniature: a short intake, a video visit that reviews how the past year went, and a new signed recommendation. Start it before the current one lapses, since a gap usually means losing dispensary access until the new card is issued. The renewal path for your state is linked from the medical card section.
Can I arrange this for a parent or a partner who is too ill to do it themselves?
In most states, yes, through a caregiver designation: a named adult who may buy and carry cannabis on behalf of a registered patient. The patient still has to be evaluated and registered, and the caregiver is usually registered too, with the state’s own form and background requirements. It is a common route in exactly this population — advanced cancer, advanced age — and the requirements are state-specific, so check yours on the laws pages and ask during the appointment.
Who finds out that I have a card?
Your consultation is a medical appointment and is handled as protected health information. State patient registries are confidential and are not published. What a card does not do is override an employer’s drug policy, federal law, or the federal rules on firearms, and those are worth understanding before you apply rather than after. The state pages set out what protections your program actually grants.
If cannabis is already legal where I live, why bother with a card?
Because the patient status is not the same as the right to buy. Depending on the state, registered patients pay lower taxes, may hold more than a recreational buyer, can access medical-only products and higher-strength formulations, and in some states may grow. For someone using cannabis for a medical reason, month after month, those differences are the practical argument — and the evaluation itself gets a physician’s eyes on the problem, which buying at a counter does not.
Other qualifying conditions
Appetite loss rarely arrives alone. These pages cover the conditions that most often sit next to it, each with its own evidence and its own answer.
References
18 sources
- 1. Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. DOI: 10.1002/eat.70034 PMID: 41906184
- 2. The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature. DOI: 10.1016/j.jnha.2024.100299 PMID: 38917597
- 3. A Phase 1B Trial of Cannabidiol for Symptom Management in Kidney Failure. DOI: 10.1016/j.ekir.2025.11.022 PMID: 41537103
- 4. Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies. DOI: 10.1111/adb.12880 PMID: 32064741
- 5. Coordinated epigenetic dysregulation of CNR1 and FAAH genes drives endocannabinoid system dysfunction in anorexia nervosa. DOI: 10.1186/s40337-025-01472-y PMID: 41310856
- 6. The Problem of Appetite Loss After Major Abdominal Surgery: A Systematic Review. DOI: 10.1097/SLA.0000000000005379 PMID: 35129465
- 7. A Dimer for Dinner: The Impact of GHS-R1a Heterodimerization on Feeding Circuits. DOI: 10.3390/biom16060788 PMID: 42352256
- 8. Effect of intracerebroventricular (ICV) injection of antimicrobial peptide expressed in the body-2 (LEAP-2) and its interaction with cannabinoid and ghrelin systems on food intake in broiler chickens. DOI: 10.1016/j.psj.2025.106199 PMID: 41406822
- 9. Effects of Sativex® Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial. DOI: 10.3390/nu18142274 PMID: 42514343
- 10. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. DOI: 10.1200/JCO.2005.05.1847 PMID: 16849753
- 11. Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis. DOI: 10.1002/jcsm.12861 PMID: 34881518
- 12. Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9-tetrahydrocannabinol in older patients with poor appetite. DOI: 10.1002/bcp.70284 PMID: 40974011
- 13. Efficacy of cannabis oil on appetite and quality of life in systemic sclerosis patients: a randomized placebo-controlled trial. DOI: 10.1186/s42238-025-00342-3 PMID: 41137182
- 14. The relationship between cannabis and anorexia nervosa: a scoping review. DOI: 10.1186/s40337-023-00887-9 PMID: 37858278
- 15. Risk of somatic diseases in patients with eating disorders: the role of comorbid substance use disorders. DOI: 10.1017/S204579602200052X PMID: 36245431
- 16. Latent classes of alcohol and cannabis use among adults with binge-spectrum eating disorders: Associations with eating disorder symptom severity and personality features. DOI: 10.1002/erv.3056 PMID: 38030958
- 17. Case Report: Substance fixation in autism spectrum disorder with resultant anorexia nervosa. DOI: 10.3389/fpsyt.2025.1630528 PMID: 41063929
- 18. Intestinal tuberculosis with perforation in an immunocompetent adult presenting with chronic abdominal pain: A case report. DOI: 10.3892/mi.2025.272 PMID: 41089391